First patients to receive 'Living Drug' in fight against tough leukemia
NCT ID NCT06834282
Summary
This is the first-ever study in people of an experimental treatment called CER-1236 for acute myeloid leukemia (AML) that has come back or is resistant to other treatments. Doctors will test the safety and early effectiveness of this therapy, which uses a patient's own immune cells that are specially engineered in a lab to find and attack leukemia cells. The study will involve a small group of adults with specific types of AML to find the right dose and see how well the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
Contact Email: •••••@•••••
Contact
-
Sarah Cannon Research Insitute
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-••••
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California, Davis Comprehensive Cancer Center
NOT_YET_RECRUITINGSacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.